| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jeffrey Weber | |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| ipilimumab | Q2459042 | ||
| P304 | page(s) | 864-872 | |
| P577 | publication date | 2007-07-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events | |
| P478 | volume | 12 |
| Q27012963 | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity |
| Q35483823 | A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes |
| Q56898845 | A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma |
| Q27006569 | A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics |
| Q41485806 | Acute visual loss after ipilimumab treatment for metastatic melanoma |
| Q33861540 | Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. |
| Q38244522 | Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies |
| Q47932000 | Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents |
| Q42908395 | Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses |
| Q40322388 | Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis |
| Q37565259 | Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes |
| Q37782273 | Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease |
| Q36440066 | Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40 |
| Q37710860 | Assessing oncologic benefit in clinical trials of immunotherapy agents |
| Q56900033 | Autoimmune inflammatory myopathy after treatment with ipilimumab |
| Q37014061 | Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma |
| Q34395229 | Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma |
| Q34652892 | CTLA-4 blockade and the renaissance of cancer immunotherapy |
| Q34355686 | CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells |
| Q37100764 | CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation |
| Q38912232 | Cancer testis antigen and immunotherapy |
| Q38636711 | Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies |
| Q35580479 | Chemokines, Costimulatory Molecules and Fusion Proteins for the Immunotherapy of Solid Tumors |
| Q39022564 | Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. |
| Q33708801 | Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients |
| Q37868974 | Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia |
| Q38007938 | Colitis associated with biological agents |
| Q37918893 | Combination of targeted therapy and immunotherapy in melanoma |
| Q50966333 | Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial |
| Q39142678 | Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. |
| Q51555848 | Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy |
| Q39371874 | Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy |
| Q51144432 | Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity. |
| Q38824724 | Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway |
| Q37483961 | Current systemic therapy for metastatic melanoma |
| Q28070095 | Cutaneous complications of molecular targeted therapy used in oncology |
| Q39763632 | Cytotoxic T-Lymphocyte–Associated Antigen-4 |
| Q56899966 | Cytotoxic T-lymphocyte antigen 4 blockade augments the T-cell response primed by attenuated Listeria monocytogenes resulting in more rapid clearance of virulent bacterial challenge |
| Q38376598 | Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme |
| Q30736359 | Designing a broad-spectrum integrative approach for cancer prevention and treatment. |
| Q34149569 | Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy |
| Q52924613 | Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. |
| Q38271490 | Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls |
| Q92524991 | Differential expression of immune related genes in high-grade ovarian serous carcinoma |
| Q42391387 | Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine |
| Q36544926 | Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody |
| Q64974782 | Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. |
| Q33620317 | Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases |
| Q37601946 | Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis |
| Q37137464 | Emerging cancer vaccines: the promise of genetic vectors. |
| Q34633278 | Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells |
| Q47830169 | Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors. |
| Q24618690 | Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma |
| Q33416009 | Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma |
| Q38483251 | Functional clustering of immunoglobulin superfamily proteins with protein-protein interaction information calibrated hidden Markov model sequence profiles |
| Q34275134 | Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine |
| Q36185580 | Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment |
| Q41111818 | Hepatic encephalopathy associated with cancer or anticancer therapy. |
| Q38037487 | How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma |
| Q50320411 | Human FOXP3+ T regulatory cell heterogeneity. |
| Q37317487 | Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors. |
| Q38201196 | Immunologic and clinical effects of targeting PD-1 in lung cancer |
| Q37174695 | Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients |
| Q56898563 | Immunotherapy for Advanced Melanoma |
| Q28088363 | Immunotherapy for Bone and Soft Tissue Sarcomas |
| Q51092888 | Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. |
| Q37266668 | Immunotherapy of distant metastatic disease. |
| Q45770749 | Immunotherapy of head and neck cancer. Current developments |
| Q38318683 | Immunotherapy of melanoma: present options and future promises. |
| Q27861062 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma |
| Q47211203 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience |
| Q39040949 | Infliximab for ipilimumab-induced colitis: A series of 13 patients |
| Q44695357 | Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C |
| Q33777476 | Ipilimumab and Its Toxicities: A Multidisciplinary Approach |
| Q51738566 | Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). |
| Q56896291 | Ipilimumab for the treatment of melanoma |
| Q33396664 | Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. |
| Q50719439 | Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm |
| Q47713862 | Ipilimumab-induced hypophysitis: MR imaging findings |
| Q42314954 | Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). |
| Q40104280 | Ipilimumab: Melanoma and beyond |
| Q50191687 | Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. |
| Q34615021 | MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro |
| Q38644422 | Markers of T Cell Senescence in Humans |
| Q37355568 | Monoclonal antibodies in the treatment of pancreatic cancer. |
| Q37755276 | Monoclonal antibody-induced cytokine-release syndrome |
| Q56898695 | Neem Leaf Glycoprotein Inhibits CD4 + CD25 + Foxp3 + Tregs to Restrict Murine Tumor Growth |
| Q56889672 | Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases |
| Q26829161 | New modalities of cancer treatment for NSCLC: focus on immunotherapy |
| Q38108836 | Novel antibodies targeting immune regulatory checkpoints for cancer therapy. |
| Q27004436 | Novel immunotherapies for hematologic malignancies |
| Q40298916 | Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. |
| Q35861933 | Oncolysis by paramyxoviruses: preclinical and clinical studies. |
| Q39756798 | Overall survival and PD-L1 expression in metastasized malignant melanoma |
| Q37220158 | Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma |
| Q83174110 | Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia |
| Q47315414 | Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers |
| Q37265479 | Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors |
| Q47151142 | Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy |
| Q40435066 | ProtLID, a Residue-Based Pharmacophore Approach to Identify Cognate Protein Ligands in the Immunoglobulin Superfamily |
| Q53732997 | Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma |
| Q38389326 | Rationale for combining immunotherapy with chemotherapy |
| Q34084756 | Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy |
| Q37055023 | Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors |
| Q36478158 | Shifting the Paradigm in Radiation Safety |
| Q34042968 | Strategies to overcome obstacles to successful immunotherapy of melanoma |
| Q38529051 | Systematic review: colitis associated with anti-CTLA-4 therapy. |
| Q37051003 | TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours |
| Q28302584 | Targeting metastatic melanoma |
| Q37590909 | Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. |
| Q46367364 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study |
| Q38035848 | The Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function |
| Q43556611 | The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q56900194 | The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management |
| Q37985890 | The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma |
| Q34057800 | The role of co-inhibitory signals driven by CTLA-4 in immune system |
| Q39045958 | The role of the immune system in neurofibromatosis type 1-associated nervous system tumors |
| Q37715703 | The safety and side effects of monoclonal antibodies |
| Q35908498 | Therapeutic Antibodies Against Cancer |
| Q56895374 | Therapeutic antibodies in cancer therapy |
| Q38312255 | Therapeutic vaccines in HBV: lessons from HCV. |
| Q38085028 | Tremelimumab: a review of development to date in solid tumors |
| Q26825850 | Vaccines for pancreatic cancer |
| Q28085434 | Vaccines versus immunotherapy: overview of approaches in deciding between options |
| Q38041073 | Why RECIST Works and Why It Should Stay—Counterpoint |
| Q39488720 | Widespread expressions of immunoglobulin superfamily proteins in cancer cells |
Search more.